ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / KYNB
ACTU (35) AKTX (37) COCP (36) MCRB (40) ⌘ Pro Terminal β†’

Kyntra Bio Inc. (KYNB) β€” RQD Stock Rating Cockpit

$4.46 -2.41% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.43

Kyntra Bio Inc. (KYNB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $18.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KYNB Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Kyntra Bio Inc. (NASDAQ: KYNB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.46 (-2.41% 1D, market cap $18.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, KYNB ranks #735 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does KYNB compare to ACTU and AKTX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KYNB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 91.4%, and ROIC of -35.0%. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, KYNB leads on earnings multiple (N/A) while KYNB leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KYNB?
β–Ό

Per KYNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921299), Kyntra Bio Inc. generated $6.4M in revenue (-78.3% YoY), $183.5M in net income, and -$4.8M in free cash flow against $119.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.43 (-0.62%)🧬 Disciplined Float (+0.16% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (4)Whales (3)SEC (12)Macro (6)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$12 Bull$4 Base$3 Bear
πŸ“¬ FREE KYNB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for KYNB)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY KYNB SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy β€’ Disciplined Float (+0.16% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$5.87-10.1% Next Q
Q2 (-2Q)
37
Grade E$5.28-14.8% Next Q
Q3 (-1Q)
35
Grade E$4.50-0.9% Next Q
Current
32
Grade E$4.46-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a KYNB Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While KYNB currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.56) and Max Pain ($4.68) forces dealer call-delta covering toward $11.96.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KYNBβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œKYNB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
RSI-14 MOMENTUMOVERSOLD (<32)
28.430 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $4$4.46H: $11
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on KYNB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with 91.4% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

10/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like KYNB
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KYNB)

  • βœ“Walkthrough of KYNB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
KYNB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.06%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $4.65H $4.65L $4.46C $4.46VOL 24.4K
RES: $9.18SUP: $4.13SMA50: $6.56SMA200: $7.06
$9.27$7.93$6.59$5.25$3.90RES $9.18SUP $4.13$4.462026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYNB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ KYNB Butterfly Map β†’ + Track KYNB β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -78.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KYNB today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for KYNB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KYNB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KYNB)

Health Care Rank #735 of 1015 βš”οΈ ACTU vs KYNB Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (KYNB vs. ACTU, AKTX, COCP, MCRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kyntra Bio Inc. (KYNB) ranks #735 by composite RQD confidence (32/100, grade E) and #834 by equity capitalization ($18.5M). Within this direct 5-issuer industry benchmark cohort, KYNB leads on earnings valuation at N/A trailing P/E, while KYNB leads on capital efficiency and profitability with -35.0% ROIC and 91.4% gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with KYNB at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KYNB ACTIVE
Kyntra Bio Inc.
E 32/100 β€” 91.4% -35.0% -2.41% $18.5M Benchmark Subject
ACTU
Actuate Therapeutics Inc.
D- 35/100 β€” β€” -35.0% +2.06% $18.4M /actu-vs-kynb β†’
AKTX
Akari Therapeutics plc ADS
D- 37/100 β€” β€” -35.0% -4.85% $18.8M /aktx-vs-kynb β†’
COCP
Cocrystal Pharma Inc.
D- 36/100 β€” β€” -35.0% +6.53% $19.2M /cocp-vs-kynb β†’
MCRB
Seres Therapeutics Inc.
D- 40/100 β€” β€” -35.0% +3.39% $17.8M /mcrb-vs-kynb β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000921299 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kyntra Bio Inc. (KYNB) reported GAAP revenue of $6.4M (-78.3% vs. FY2024 revenue of $29.6M , and -86.2% cumulative change since FY2023) , GAAP net income of $183.5M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+96.5% YoY). On the balance sheet, KYNB closed FY2025 with $119.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.4M $183.5M -$4.8M -$4.8M $119.6M β€”
FY2024 (FY) 2024-12-31 $29.6M -$47.6M -$138.0M -$138.3M $214.5M β€”
FY2023 (FY) 2023-12-31 $46.8M -$284.2M -$315.0M -$315.0M β€” β€”

3. KYNB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kyntra Bio Inc. (NASDAQ: KYNB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.46 (-2.41% 1D, market cap $18.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, KYNB ranks #735 in composite RQD confidence.

How does KYNB compare to ACTU and AKTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KYNB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 91.4%, and ROIC of -35.0%. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, KYNB leads on earnings multiple (N/A) while KYNB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KYNB?

Per KYNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921299), Kyntra Bio Inc. generated $6.4M in revenue (-78.3% YoY), $183.5M in net income, and -$4.8M in free cash flow against $119.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KYNB trading relative to its 50-day, 200-day, and 52-week technical levels?

KYNB last traded at $4.46 (-2.41% on volume of 15,293 shares), positioning the stock -32.01% below its 50-day simple moving average ($6.56) and -36.83% below its 200-day simple moving average ($7.06). Across its 52-week range of $4.32 to $11.39, KYNB sits at the 2.0% percentile with a 14-day RSI of 28.4 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($3.90 to $5.02).

Direct Sub-Reports: KYNB RQD Cockpit KYNB 12M Forecast KYNB Earnings & Move KYNB Dividends & DRIP KYNB Insiders & 13F KYNB Whale Options KYNB Profit Sankey KYNB News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

KYNB β€” Kyntra Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kyntra Bio Inc. (KYNB) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.46 (-2.41% 1D, market capitalization $18.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 91.4%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kyntra Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, the company reports a gross margin of 91.4%, indicating a high gross margin profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kyntra Bio Inc. (KYNB) reported $6.4M in annual revenue (up from $29.6M in FY2024, -78.3% YoY) and $183.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.8M revenue, -$284.2M net income) through FY2025, KYNB scaled operating cash flow to -$4.8M and free cash flow to -$4.8M, backed by $119.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.32 – $11.39 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation mappings are therefore β€” A prospective investor should note that any second-order ripple analysis cannot be derived from the provided graph; the most material second-order risk visible in the sources is the listing-status question, which could affect liquidity and institutional eligibility.

  • Key Question #1: Can KYNB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.4M and free cash flow of -$4.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KYNB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KYNB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kyntra Bio Inc. (KYNB) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to KYNB Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KYNB Bull vs. Bear Conversation Board β€” What's Your Call at $4.46?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KYNB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KYNB:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $5.39 (+17.9%)
πŸ“Œ Pinned Debate

Maxim initiated coverage with a Buy rating and a $35 price target, and the company reports a 91.4% gross margin.

Here is why I am bullish on KYNB here at $4.57: Maxim initiated coverage with a Buy rating and a $35 price target, and the company reports a 91.4% gross margin.. Compare KYNB's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.34 are getting bought.

EarningsSniper πŸ‚ BULL

Both sides have a point here β€” KYNB's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.56 (-22.1%)
Spot @ $4.57

Revenue fell from $46.8M in FY 2023 to $6.4M in FY 2025 while ROIC sits at -35% and the company faces a Nasdaq delisting notice.

I respect the product at Kyntra Bio Inc., but the stock at $4.57 is a different story. Revenue fell from $46.8M in FY 2023 to $6.4M in FY 2025 while ROIC sits at -35% and the company faces a Nasdaq delisting notice.. FCF yield is 0.0% and RQD sits at 32/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE